Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 10/2013

01-10-2013 | Research Article

Expression of p53 upregulated modulator of apoptosis (PUMA) and C-myb in gallbladder adenocarcinoma and their pathological significance

Authors: W. Cai, Q. Li, Z. Yang, X. Miao, Y. Wen, S. Huang, J. Ouyang

Published in: Clinical and Translational Oncology | Issue 10/2013

Login to get access

Abstract

Purpose

An increasing number of studies have shown that PUMA and C-myb signaling pathways are involved in various human cancers including colon carcinomas. However, few studies have examined gallbladder cancer specimens, and little is known about the clinical and pathological significance signaling changes may have in gallbladder adenocarcinoma. This study has investigated the expression of PUMA and C-myb in benign and malignant lesions of gallbladder and its pathological significance.

Methods

Tissue specimens from 108 gallbladder adenocarcinoma patients, 46 adjacent tissues, 15 cases of adenomatous polyps, and 35 surgical specimens from chronic cholecystitis patients were routinely paraffin embedded and sectioned. PUMA and C-myb expressions were detected with EnVision immunohistochemistry.

Results

Positive rates of PUMA and C-myb are significantly higher in gallbladder adenocarcinoma tissues than that in the other three (P < 0.01). Gallbladder epithelial cells in PUMA and/or C-myb positive benign cases manifest moderate to severe atypical dysplasia. Positive rates of PUMA and C-myb in well-differentiated tumors with maximum diameter of <2 cm and with no lymph node metastasis and invasion of the surrounding tissues are significantly lower than that in those poorly differentiated cases with maximum diameter of ≥2 cm, lymph node metastasis, and invasion of the surrounding tissues (P < 0.05 or P < 0.01). The postoperative survival of patients whose tumor specimens are positive for PUMA and C-myb is significantly shorter than that of those who are negative for both markers (P < 0.05 or P < 0.01).

Conclusions

Our results have demonstrated that PUMA and C-myb positive gallbladder tumors progress rapidly, are prone to metastasis, possess strong invasive ability, and have poor prognosis.
Literature
1.
2.
3.
Yee KS, Wikinson S, James J, Ryan KM, Vousden KH (2009) PUMA and Bax-induced autophagy contributes to apoptosis. Cell Death Differ 16(8):1135–1145PubMedCrossRef
4.
Sinicrope FA, Rego RL, Okumura K, Foster NR, O’Connell MJ, Sargent DJ et al (2008) Prognostic impact of bin, puma, and noxa expression in human colon carcinomas. Clin Cancer Res 14(18):5810–5818PubMedCrossRef
5.
Diallo JS, Aldejmah A, Mouhim AF, Péant B, Fahmy MA, Koumakpayi IH et al (2007) NoXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin Cancer Res 13(23):7044–7052PubMedCrossRef
6.
Ransay RG, Gonda TJ (2008) MYB function in normal and cancer cells. Nat Rev Cancer 8(7):523–534
7.
Oh IH, Reddy EP (1999) The myb gene family in cell growth, differentiation and apoptosis. Oncogene 18(19):3017–3033PubMedCrossRef
8.
Gonda TJ, Leo P, Ramsay RG (2008) Estrogen and MYB in breast cancer: Potential for new therapies. Expert Opin Biol Ther 8(6):713–717PubMedCrossRef
9.
Wilkins HR, Doucet K, Duke V, Morra A, Johnson N (2010) Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing C-myb protein, and decreasing transcription of the anti-apoptosis protein bcl-2. Tumor Biol 31(1):16–22CrossRef
10.
Yang H, Huang ZZ, Wang J, Lu SC (2001) The role of C-myb and SP1 in the up-regulation of methionine adenosyltransferase 2A gene expression in human hepatocellular carcinoma. FASEB J 15(9):1507–1516PubMedCrossRef
11.
Brabender J, Lord RV, Danenberg KD, Metzger R, Schneider PM, Park JM et al (2001) Increased C-mybmRNA expression in Barrettses ophagusand Barretts-associated adenocarcinoma. J Surg Res 99(2):301–306PubMedCrossRef
12.
Nürnberg W, Artuc M, Nawrath M, Lovric J, Stüting S, Moelling K et al (1995) Human C-myb is expressed in cervical carcinomas and transactivates the HPV-16 promoter. Cancer Res 55(19):4432–4437PubMed
13.
Kim SY, Yang YS, Hong KH, Jang KY, Chung MJ, Lee DY et al (2008) Adenovirus-mediated expression of dominant negative c-myb induces apoptosis in head and neck cancer cells and inhibits tumor growth in animal model. Oral Oncol 44(4):383–392PubMedCrossRef
14.
Hoque MO, Begum S, Sommer M, Lee T, Trink B, Ratovitski E et al (2003) Puma in head and neck cancer. Cancer Lett 199(1):75–81PubMedCrossRef
15.
Jansson A, Arbman G, San XF (2004) mRNA and protein expression of PUMA in sporadic colorectal cancer. Oncol Rep 12(6):1245–1249PubMed
Metadata
Title
Expression of p53 upregulated modulator of apoptosis (PUMA) and C-myb in gallbladder adenocarcinoma and their pathological significance
Authors
W. Cai
Q. Li
Z. Yang
X. Miao
Y. Wen
S. Huang
J. Ouyang
Publication date
01-10-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 10/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1010-8

Other articles of this Issue 10/2013

Clinical and Translational Oncology 10/2013 Go to the issue

Research Article

Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma

Educational series - Blue Series

Ependymoma in children: molecular considerations and therapeutic insights

Research Article

Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences

Brief Research Article

Profiles of circulating endothelial cells and serum cytokines during adjuvant chemoradiation in rectal cancer patients

Research Article

Expression and prognostic role of c-Myb as a novel cell cycle protein in esophageal squamous cell carcinoma

Educational Series - Red Series

Consensus on the regional lymph nodes irradiation in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits